International Pharmaceutical Aerosol Consortium
Budget
€100 — €0
EP Access
0
accredited persons
Staff
2
0.5 FTE
EU Grants
None
Mission & Goals
The International Pharmaceutical Aerosol Consortium (IPAC) was formed in 1989 in response to the mandates of the Montreal Protocol on Substances that Deplete the Ozone Layer and fully supported a timely and effective transition away from chlorofluorocarbons (CFCs) used in pressurised metered dose inhalers (pMDIs) under the Montreal Protocol that balanced patient health and environmental concerns. IPAC’s mission is to ensure that environmental policies relevant to inhaled therapies are patient-centric and appropriately balance both patient care and sustainability objectives. IPAC members research and develop CFC-free products – HFC pMDIs, dry powder inhalers (DPIs) and soft mist inhalers (SMIs). In light of this history and deep expertise, IPAC is uniquely positioned to serve as a resource in efforts related to the intersection of environmental policies and inhaled therapies. IPAC’s members are AstraZeneca, Bespak, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kindeva, & Teva.
EU Legislative Interests
IPAC's focus is on environmental/climate change policies related to fluorinated gases and, in particular, hydrofluorocarbons (HFCs) 134a and 227ea which are used as aerosol propellants in inhaled therapies. IPAC members are developing next generation lower global warming potential medical propellants: HFC-152a and HFO-1234ze(E). IPAC engages with the Commission and other stakeholders on the implementation of the European F-Gases Regulation: 2024/573. IPAC is also participating in public consultations relevant to the ECHA REACH proposed restriction on PFAS.
Communication Activities
IPAC's recent activities are summarized below. IPAC has engaged with the European Commission, European Medicines Agency, staff/members of Parliament, and Council on issues relevant to the implementation of the F-Gas regulation. An area of focus was new labelling requirements of the F-Gas regulation as well as other compliance matters relevant to the quota system and customs procedures. IPAC also responded to a public questionnaire on ECHA Reach/PFAS issues in May and September 2023 and September. Copies are available on www.ipacinhaler.org. IPAC continues to monitor developments relevant to the ECHA REACH process.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
IPAC is an associate member of the Alliance for Responsible Atmospheric Policy, please see: http://alliancepolicy.org/ and of the Household & Commercial Products Association (HCPA): https://www.thehcpa.org/.
Organisation Members
IPAC’s members are AstraZeneca, Bespak, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kindeva, and Teva. See www.ipacinhaler.org.
Commissioner Meetings
No recorded meetings with EU commissioners.